research A Review of Janus Kinase Inhibitor Use in Scarring Alopecia
Janus kinase inhibitors (JAKis) show promise in treating scarring alopecias, which are challenging due to irreversible hair follicle destruction. This review highlights the effectiveness of oral JAKis like tofacitinib, baricitinib, and upadacitinib in improving conditions such as lichen planopilaris (LPP) and frontal fibrosing alopecia (FFA), with significant clinical improvements noted. Topical JAKis, including tofacitinib and ruxolitinib, are effective for localized conditions. Brepocitinib, a dual TYK2/JAK1 inhibitor, has shown positive results in a phase 2a trial for LPP, FFA, and central centrifugal cicatricial alopecia. However, further research is needed to refine treatment protocols, ensure long-term safety, and develop personalized treatment strategies based on disease subtype and patient characteristics.
